- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05055323
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
A Phase I Dose Escalation Study Using Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the safety and tolerability of pyrvinium pamoate (PP), dosed orally, in patients with pancreatic ductal adenocarcinoma (PDAC) that are surgical candidates.
SECONDARY OBJECTIVE:
I. Assessment of PP's pharmacokinetic and pharmacodynamic (PK/PD) profile and bioavailability in humans.
OUTLINE: This is a dose-escalation study.
Patients receive pyrvinium pamoate orally (PO) once daily (QD) for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
After completion of study treatment, patients are followed up for 30 days and then every week for up to 4 weeks.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Harish Lavu, MD
- Phone Number: 215-955-9402
- Email: harish.lavu@jefferson.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University
-
Contact:
- Harish Lavu, MD
- Phone Number: 215-955-9402
- Email: harish.lavu@jefferson.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) suspected preoperatively who are deemed to be surgical candidates by the Thomas Jefferson University surgery department. Patients will be assessed by the pancreatic surgeons in the pancreatic surgery clinic, and if they are found to have resectable disease, they can be considered for this study
- Patients must not be on neoadjuvant therapy, or have received their last neoadjuvant treatment greater than or equal to within three weeks of starting PP therapy
- Provide signed and dated informed consent form
- Willing to comply with all study procedures and be available for the duration of the study
- Patients must have an estimated life expectancy of > 3 months, and Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
All patients regardless of age or gender must agree to observe proper contraceptive methods as to avoid becoming pregnant or causing pregnancy for the duration of the study (30 days after last dose of drug)
- Males will practice safe sex methods (i.e. condoms)
- Women of child bearing potential will practice safe sex methods (i.e. condoms, birth control), if a female on the study is of child-bearing age, they will have to take a urine human chorionic gonadotropin (HCG) (pregnancy) test prior to enrolling on the study
Exclusion Criteria:
- Patients with ongoing anticancer therapies, or those who will have received an anticancer therapeutic <3 weeks prior to the first dose of PP
- Any condition that precludes pancreatic surgical resection at the time of the study
- Pregnancy or currently breastfeeding
- Known allergic reactions to components of the study product(s): pyrvinium pamoate/ pyrvinium embonate (Molevac)
- Patients with chronic bowel conditions (such as inflammatory bowel disease (IBD))
- Kidney function impairment (serum creatine > 1.5 x ULN or creatine clearance </= 60 ml/1.73m^2 fr patients with creatine levels > 1.5 x ULN).
Patients with liver function impairment: Alkaline phosphatase, ALT and AST above three folds the normal limit (see normal ranges); Total Bilirubin level > 3mg/dl; Albumin < 3g/dl
* Alkaline phosphatase:
- 0-9 years (yr): 83-280 IU/L at 37 degrees Celsius
- 10-14 yr: 91-400
- 15-17 yr: 37-240
- 18-49 yr: 29-92
- 50-74 yr: 25-120
- 75-97 yr: 29-160
- 98-99 yr: 29-120
- > 99 yr: 29-160
Patients with liver function impairment outside of the below ranges
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]):
** Male (M): 1-45 IU/L at 37 degrees Celsius
** Female (F): 1-30
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]):
- M: 7-42 IU/L at 37 degrees Celsius
- F: 7-35
Patients with liver function impairment outside of the below ranges
* Albumin:
- 0-1 yr: 2.6-4.4
- 1-15 yr: 3.0-4.7
- 16-99 yr: 3.2-4.9
Patients with liver function impairment outside of the below ranges
* Bilirubin, total:
** 0.1-0.9 mg/dL
Patients with liver function impairment outside of the below ranges * Protein, total:
- 0-1 yr: 4.6-7.2 g/dL
- 1-15 yr: 5.7-8.2
- 16-99 yr: 6.0-8.5
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (pyrvinium pamoate)
Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity.
Patients then undergo standard of care surgery.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose limited toxicity (DLT)
Time Frame: Up to 30 days from last dose
|
Considered any grade 3 or higher adverse event due to the drug itself or delay of surgery.
Research coordinator will call patient every day to monitor for DLTs.
|
Up to 30 days from last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Profile of pyrvinium pamoate (PP)
Time Frame: At Start of Treatment
|
Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).
|
At Start of Treatment
|
Profile of pyrvinium pamoate (PP)
Time Frame: Completion of treatment
|
Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).
|
Completion of treatment
|
Bioavailability of PP
Time Frame: Up to 4 weeks
|
Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).
|
Up to 4 weeks
|
Fatty tissue accumulation of PP
Time Frame: Up to 4 weeks
|
Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).
|
Up to 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Harish Lavu, MD, Thomas Jefferson University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Adenocarcinoma
- Pancreatic Neoplasms
- Anti-Infective Agents
- Antiparasitic Agents
- Anthelmintics
- Pyrvinium
Other Study ID Numbers
- 20F.041
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II Pancreatic Cancer AJCC v8
-
Thomas Jefferson UniversitySuspendedMalignant Solid Neoplasm | Gastric Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Colorectal Adenocarcinoma | Small Intestinal Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditionsUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)CompletedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer... and other conditionsUnited States
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH); National...RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Squamous Cell... and other conditionsUnited States
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; Servier Pharmaceuticals...RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnPancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Homologous Recombination Deficiency | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | ATM Gene Mutation | Deleterious BRCA1 Gene... and other conditions
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IV Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb FoundationCompletedStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Neoplasm | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal... and other conditionsUnited States
-
Flemming ForsbergNational Cancer Institute (NCI)RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...United States, Norway
Clinical Trials on Pyrvinium Pamoate
-
IpsenCompletedCentral Precocious PubertyChina
-
IpsenCompletedProstate CancerPoland, Romania, Bulgaria, Latvia, France
-
IpsenActive, not recruitingMetastatic Prostate Cancer | Advanced Prostate Cancer | Locally Advanced Prostate CancerChina
-
Novartis PharmaceuticalsCompletedHealthy CholecystectomizedFrance, Italy, Belgium
-
IpsenCompletedPrecocious PubertyFrance
-
IpsenCompleted
-
AEterna ZentarisCompletedBenign Prostatic HypertrophyUnited States, Canada
-
Children's Hospital Medical Center, CincinnatiWatson PharmaceuticalsCompletedSystemic Lupus ErythematosusUnited States, Brazil
-
National Taiwan University HospitalDebiopharm International SA; Ministry of Health and WelfareNot yet recruitingTriple Negative Breast Cancer | Premenopausal Breast Cancer